ABSTRACT
WHAT IS THIS SUMMARY ABOUT?: This is a plain language summary discussing the results of our study published in the journal Nanomedicine. The study describes how to improve the detection of blood cancer and chart the progress of recovery/remission to reassure patients living with cancer. WHAT DID WE DO?: In our study, we used a new tool called Raman spectroscopy to detect molecules found uniquely in the blood plasma of people with, or recovering from, blood cancer. Our aim was to fine-tune this technique so that it could help doctors better determine if cancer was growing back or not responding to treatment. Gold nanoparticles were used to enhance the signal of these cancer-specific molecules so that Raman spectroscopy (also called nanoSERS) could better identify and expose the cancer in hiding. WHAT IS THE IMPORTANCE OF THESE FINDINGS?: We discovered that this new tool (Raman spectroscopy using gold nanoparticles) can detect trace molecules in the blood found only when cancer cells are present or when a person's cancer is returning. This study, which has identified new potential for Raman spectroscopy as an early-screening tool, opens the possibility for the better monitoring of blood cancer. This could mean both less aggressive and fewer treatments for people diagnosed with this disease. This tool may also be useful for people seeking reassurance that their cancer remains dormant or will be identified for treatment sooner if it returns. These findings can also be applied more broadly, such as in helping scientists test the effectiveness of new treatments as they continue to get better at eliminating cancer cells.
Subject(s)
Hematologic Neoplasms , Metal Nanoparticles , Neoplasms , Humans , Spectrum Analysis, Raman/methods , Gold/chemistry , Metal Nanoparticles/chemistryABSTRACT
DNA methylation is an essential epigenetic mark in mammals that has to be re-established after each round of DNA replication. The protein UHRF1 is essential for this process; it has been proposed that the protein targets newly replicated DNA by cooperatively binding hemi-methylated DNA and H3K9me2/3, but this model leaves a number of questions unanswered. Here, we present evidence for a direct recruitment of UHRF1 by the replication machinery via DNA ligase 1 (LIG1). A histone H3K9-like mimic within LIG1 is methylated by G9a and GLP and, compared with H3K9me2/3, more avidly binds UHRF1. Interaction with methylated LIG1 promotes the recruitment of UHRF1 to DNA replication sites and is required for DNA methylation maintenance. These results further elucidate the function of UHRF1, identify a non-histone target of G9a and GLP, and provide an example of a histone mimic that coordinates DNA replication and DNA methylation maintenance.
Subject(s)
CCAAT-Enhancer-Binding Proteins/metabolism , DNA Ligase ATP/metabolism , DNA Methylation , DNA Replication , DNA/biosynthesis , Epigenesis, Genetic , Histocompatibility Antigens/metabolism , Histone-Lysine N-Methyltransferase/metabolism , Protein Processing, Post-Translational , Animals , CCAAT-Enhancer-Binding Proteins/chemistry , CCAAT-Enhancer-Binding Proteins/genetics , DNA/genetics , DNA Ligase ATP/chemistry , DNA Ligase ATP/genetics , Embryonic Stem Cells/enzymology , HEK293 Cells , HeLa Cells , Histocompatibility Antigens/chemistry , Histocompatibility Antigens/genetics , Histone-Lysine N-Methyltransferase/chemistry , Histone-Lysine N-Methyltransferase/genetics , Histones/metabolism , Humans , Lysine , Methylation , Mice , Models, Molecular , Molecular Mimicry , Mutation , Protein Binding , Protein Conformation , Structure-Activity Relationship , Transfection , Tudor Domain , Ubiquitin-Protein LigasesABSTRACT
MBD5 and MBD6 are two members of the methyl-CpG-binding domain (MBD) family of proteins that are poorly characterized. Studies performed thus far have failed to show binding of the MBD5 and MBD6 MBD to methylated DNA. Here, we show that both MBD5 and MBD6 interact with the mammalian PR-DUB Polycomb protein complex in a mutually exclusive manner. Strikingly, the MBD of MBD5 and MBD6 is both necessary and sufficient to mediate this interaction. Chromatin immunoprecipitation analyses reveal that MBD6 and FOXK2/PR-DUB share a subset of genomic target genes, suggesting a functional interaction in vivo. Finally, we show that MBD6, but not MBD5, is recruited to sites of DNA damage in a PR-DUB independent manner. Our study thus implies a shared function for MBD5 and MBD6 through an interaction with PR-DUB, as well as an MBD6-specific recruitment to sites of DNA damage.
Subject(s)
DNA-Binding Proteins/metabolism , Polycomb-Group Proteins/metabolism , Amino Acid Sequence , Chromatin , DNA Damage , DNA Methylation , Forkhead Transcription Factors , HEK293 Cells , HeLa Cells , Humans , Molecular Sequence Data , Protein Binding , Protein Structure, Tertiary , Tumor Suppressor Proteins/metabolism , Ubiquitin Thiolesterase/metabolismABSTRACT
Methylated DNA can be specifically recognized by a set of proteins called methyl-CpG-binding proteins (MBPs), which belong to three different structural families in mammals: the MBD family, the Kaiso and Kaiso-like proteins and the SRA domain proteins. A current view is that, once bound to methylated DNA, MBPs translate the DNA methylation signal into appropriate functional states, through interactions with diverse partners. However, if some of the biological functions of MBPs have been widely described--notably transcriptional repression--others are poorly understood, and more generally the extent of MBP activities remains unclear. Here we propose to discuss the role of MBPs in two crucial nuclear events: chromatin organization and epigenome maintenance. Finally, important challenges for future research as well as for biomedical applications in pathologies such as cancers--in which DNA methylation patterns are widely altered--will be mentioned.
Subject(s)
Chromatin/metabolism , DNA-Binding Proteins/metabolism , Epigenesis, Genetic , Genome , Animals , Binding Sites , CpG Islands , DNA/chemistry , DNA/metabolism , DNA Methylation , DNA-Binding Proteins/genetics , HumansABSTRACT
Epigenetic perturbations are increasingly described in cancer cells where they are thought to contribute to deregulated gene expression and genome instability. Here, we report the first evidence that a distinct category of chromosomal translocations observed in human tumours--those targeting 1q12 satellite DNA--can directly mediate such perturbations by promoting the formation of aberrant heterochromatic foci (aHCF). By detailed investigations of a 1q12 translocation to chromosome 2p, in a case of human B cell lymphoma, aberrant aHCF were shown to be localized to the nuclear periphery and to arise as a consequence of long range 'pairing' between the translocated 1q12 and chromosome 2 centromeric regions. Remarkably, adjacent 2p sequences showed increased levels of repressive histone modifications, including H4K20me3 and H3K9me3, and were bound by HP1. aHCF were associated to aberrant spatial localization and deregulated expression of a novel 2p gene (GMCL1) that was found to have prognostic impact in diffuse large B cell lymphoma. Thus constitutive heterochromatin rearrangements can contribute to tumourigenesis by perturbing gene expression via long range epigenetic mechanisms.
Subject(s)
Cell Nucleus/genetics , Chromosomes, Human, Pair 1/genetics , Gene Expression Regulation, Neoplastic , Heterochromatin/genetics , Lymphoma, B-Cell/genetics , Translocation, Genetic , Chromosomes, Human, Pair 2/genetics , HumansABSTRACT
CD95 gene and splicing aberrations have been detected in B-cell non-Hodgkin lymphoma (B-NHL) where they are thought to contribute to CD95 apoptosis resistance. To further investigate this, we have performed extensive CD95 transcript sequencing and functional analysis in B-NHL with demonstrated resistance to CD95-induced apoptosis (B-NHLr). Strikingly, instead of showing CD95 mutations per se, B cells from B-NHLr co-expressed wild-type and multiple, normal (CD95nv) and novel alternatively spliced variant CD95 transcripts (CD95av). CD95av were predicted, by sequencing, to encode soluble, potentially apoptosis inhibitory proteins. However, their overexpression, by transfection, in Jurkat cells did not interfere with endogenous CD95 death signalling. Furthermore, CD95av-expressing B-NHLr did not show mutations in CD95 splice-regulatory elements and CD95av expression was 'reversible' by CD40 activation. This, in conjunction with treatment by the protein synthesis inhibitor, cycloheximide, could sensitise a subset of B-NHLr to CD95 apoptosis. In normal and lymphoma B cells, this correlated to increased CD95 membrane expression, enhanced DISC activity and engagement of the mitochondrial death pathway via Bid cleavage, although the latter occurred less efficiently in B-NHLr. Thus, immune modulation of CD95 transcription and alternative splicing combined with enhanced engagement of mitochondrial death signalling offer potential for restoration of CD95 apoptosis sensitivity in B-NHLr.
Subject(s)
Apoptosis , CD40 Antigens/metabolism , Lymphoma, B-Cell/pathology , fas Receptor/genetics , Apoptosis Regulatory Proteins , Base Sequence , Humans , Jurkat Cells , Mitochondrial Proteins , Protein Isoforms , RNA, Messenger/genetics , Signal Transduction , TransfectionABSTRACT
Although there is now evidence that the expression of centromeric (CT) and pericentric (PCT) sequences are key players in major genomic functions, their transcriptional status in human cells is still poorly known. The main reason for this lack of data is the complexity and high level of polymorphism of these repeated sequences, which hampers straightforward analyses by available transcriptomic approaches. Here a transcriptomic macro-array dedicated to the analysis of CT and PCT expression is developed and validated in heat-shocked (HS) HeLa cells. For the first time, the expression status of CT and PCT sequences is analyzed in a series of normal and cancer human cells and tissues demonstrating that they are repressed in all normal tissues except in the testis, where PCT transcripts are found. Moreover, PCT sequences are specifically expressed in HS cells in a Heat-Shock Factor 1 (HSF1)-dependent fashion, and we show here that another independent pathway, involving DNA hypo-methylation, can also trigger their expression. Interestingly, CT and PCT were found illegitimately expressed in somatic cancer samples, whereas PCT were repressed in testis cancer, suggesting that the expression of CT and PCT sequences may represent a good indicator of epigenetic deregulations occurring in response to environmental changes or in cell transformation.